What Researchers Did
This open-label, randomised controlled clinical trial investigated the efficacy and safety of autologous bone marrow mononuclear cell (BM-MNC) infusion, with or without hyperbaric oxygen therapy (HOT), for type 2 diabetes mellitus.
What They Found
Among 80 patients, the area under the curve of C-peptide significantly improved at 12 months in the BM-MNC+HOT group (34.0% from baseline) and the BM-MNC group (43.8% from baseline). These improvements were significant compared to the control group, while the HOT-only group showed no remarkable change. Treatment-related adverse events were mild, including transient abdominal pain (n=5) and punctual hemorrhage (n=3).
Canadian Relevance
This study was not conducted in Canada and does not have a direct Canadian connection.
Study Limitations
Limitations include its single-center, open-label design and relatively small sample size.